Key points from article :
Researchers at Newcastle University in the UK, supported by a grant from the Medical Research Council, are exploring the use of Athersys’ innovative MultiStem® therapy in improving kidney transplantation outcomes. MultiStem, a stem-cell-based therapy, will be studied during machine perfusion, a process where fluids are circulated through a kidney outside the body to preserve it before transplantation. The study aims to uncover how MultiStem’s regenerative properties can reduce damage caused by ischemia (a lack of blood flow) and improve organ viability for transplant.
Previous research by Athersys and Newcastle University has shown that administering MultiStem’s research-grade equivalent, MAPC® cells, during machine perfusion led to healthier, more transplant-ready kidneys. The therapy demonstrated benefits like reducing inflammation, limiting acute kidney injury, and improving organ function. This new study seeks to refine delivery methods and deepen understanding of the therapy’s mechanisms, potentially expanding its application to other medical conditions, such as heart attacks and strokes. If successful, the findings could lead to better organ availability, reduced transplant wait times, and improved outcomes for patients.
